179 related articles for article (PubMed ID: 17202245)
1. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.
Weiss J; Rose J; Storch CH; Ketabi-Kiyanvash N; Sauer A; Haefeli WE; Efferth T
J Antimicrob Chemother; 2007 Feb; 59(2):238-45. PubMed ID: 17202245
[TBL] [Abstract][Full Text] [Related]
2. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
3. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.
Storch CH; Ehehalt R; Haefeli WE; Weiss J
J Pharmacol Exp Ther; 2007 Oct; 323(1):257-64. PubMed ID: 17652262
[TBL] [Abstract][Full Text] [Related]
4. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
Gupta A; Unadkat JD; Mao Q
J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
[TBL] [Abstract][Full Text] [Related]
5. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.
Herzog M; Storch CH; Gut P; Kotlyar D; Füllekrug J; Ehehalt R; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):1-11. PubMed ID: 20936466
[TBL] [Abstract][Full Text] [Related]
7. Interactions of cyclosporin a with breast cancer resistance protein.
Xia CQ; Liu N; Miwa GT; Gan LS
Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
[TBL] [Abstract][Full Text] [Related]
8. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
9. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
10. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
12. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Wang X; Nitanda T; Shi M; Okamoto M; Furukawa T; Sugimoto Y; Akiyama S; Baba M
Biochem Pharmacol; 2004 Oct; 68(7):1363-70. PubMed ID: 15345326
[TBL] [Abstract][Full Text] [Related]
13. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
14. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Singh MS; Juvale K; Wiese M; Lamprecht A
Eur J Pharm Sci; 2015 Sep; 77():1-8. PubMed ID: 25976226
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
19. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
